Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities (2016)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Gains from Investment Securities of $1000.0 for Q4 2016, up 125.0% quarter-over-quarter from -$4000.0 in Q3 2016.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities (2016) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $1000.0 for Q4 2016.
- In Q4 2016, Gains from Investment Securities changed N/A year-over-year to $1000.0; the TTM figure through Dec 2017 stood at -$3000.0 (changed N/A YoY), while the FY2016 annual figure was $3000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q4 2016 stood at $1000.0, up from -$4000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $1000.0 in Q4 2016, with the low at -$4000.0 in Q3 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - |